Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Source: 
Clinical Trials Arena
snippet: 

Jazz Pharmaceuticals’ efforts to get its cannabidiol therapy approved in Japan have hit a snag after a Phase III trial in Japan evaluating the therapy failed to meet its primary endpoint.